Switch to:
Also traded in: Brazil, Chile, Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.10
CVS's Cash-to-Debt is ranked lower than
93% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.51 vs. CVS: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
CVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.14 Max: 5.31
Current: 0.1
0.04
5.31
Equity-to-Asset 0.38
CVS's Equity-to-Asset is ranked higher than
54% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.34 vs. CVS: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
CVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.51 Max: 0.67
Current: 0.38
0.37
0.67
Debt-to-Equity 0.74
CVS's Debt-to-Equity is ranked lower than
74% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.55 vs. CVS: 0.74 )
Ranked among companies with meaningful Debt-to-Equity only.
CVS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04  Med: 0.33 Max: 0.82
Current: 0.74
0.04
0.82
Debt-to-EBITDA 2.20
CVS's Debt-to-EBITDA is ranked lower than
53% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.05 vs. CVS: 2.20 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CVS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.14  Med: 1.39 Max: 2.37
Current: 2.2
1.14
2.37
Interest Coverage 9.32
CVS's Interest Coverage is ranked lower than
63% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.39 vs. CVS: 9.32 )
Ranked among companies with meaningful Interest Coverage only.
CVS' s Interest Coverage Range Over the Past 10 Years
Min: 9.32  Med: 11.43 Max: 15.55
Current: 9.32
9.32
15.55
Piotroski F-Score: 6
Altman Z-Score: 3.67
Beneish M-Score: -2.76
WACC vs ROIC
4.54%
9.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 5.14
CVS's Operating Margin % is ranked higher than
58% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.13 vs. CVS: 5.14 )
Ranked among companies with meaningful Operating Margin % only.
CVS' s Operating Margin % Range Over the Past 10 Years
Min: 5.14  Med: 6.3 Max: 6.91
Current: 5.14
5.14
6.91
Net Margin % 2.76
CVS's Net Margin % is ranked lower than
54% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.24 vs. CVS: 2.76 )
Ranked among companies with meaningful Net Margin % only.
CVS' s Net Margin % Range Over the Past 10 Years
Min: 2.76  Med: 3.44 Max: 3.76
Current: 2.76
2.76
3.76
ROE % 14.34
CVS's ROE % is ranked higher than
50% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.08 vs. CVS: 14.34 )
Ranked among companies with meaningful ROE % only.
CVS' s ROE % Range Over the Past 10 Years
Min: 9.14  Med: 11.33 Max: 14.37
Current: 14.34
9.14
14.37
ROA % 5.40
CVS's ROA % is ranked higher than
56% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.31 vs. CVS: 5.40 )
Ranked among companies with meaningful ROA % only.
CVS' s ROA % Range Over the Past 10 Years
Min: 5.4  Med: 5.97 Max: 7
Current: 5.4
5.4
7
ROC (Joel Greenblatt) % 75.72
CVS's ROC (Joel Greenblatt) % is ranked lower than
52% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 115.09 vs. CVS: 75.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.72  Med: 49.64 Max: 75.72
Current: 75.72
41.72
75.72
3-Year Revenue Growth Rate 16.70
CVS's 3-Year Revenue Growth Rate is ranked higher than
78% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.60 vs. CVS: 16.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.3  Med: 12.1 Max: 16.7
Current: 16.7
-13.3
16.7
3-Year EBITDA Growth Rate 11.80
CVS's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 11.60 vs. CVS: 11.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -29.4  Med: 10.8 Max: 43.7
Current: 11.8
-29.4
43.7
3-Year EPS without NRI Growth Rate 9.40
CVS's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.40 vs. CVS: 9.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.3  Med: 14.6 Max: 112.8
Current: 9.4
-48.3
112.8
GuruFocus has detected 1 Warning Sign with CVS Health Corp CVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CVS's 30-Y Financials

Financials (Next Earnings Date: 2018-02-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

CVS Guru Trades in Q4 2016

Wallace Weitz 121,162 sh (New)
Arnold Van Den Berg 69,740 sh (New)
John Rogers 33,499 sh (New)
Richard Snow 3,995 sh (New)
Ray Dalio 109,013 sh (New)
Paul Tudor Jones 28,945 sh (+323.73%)
Joel Greenblatt 1,055,841 sh (+139.61%)
Manning & Napier Advisors, Inc 190,110 sh (+118.49%)
Barrow, Hanley, Mewhinney & Strauss 18,280,528 sh (+100.88%)
Charles de Vaulx 1,384,235 sh (+96.77%)
NWQ Managers 1,352,559 sh (+44.82%)
Pioneer Investments 7,679,466 sh (+38.79%)
Steven Cohen 112,900 sh (+37.41%)
Robert Olstein 140,000 sh (+29.63%)
First Pacific Advisors 161,800 sh (+23.01%)
Jeff Auxier 62,049 sh (+18.87%)
John Buckingham 45,261 sh (+5.35%)
Scott Black 24,241 sh (+3.17%)
Ken Fisher 134,917 sh (+1.64%)
Richard Pzena 533,748 sh (+0.73%)
Mario Gabelli 1,071,617 sh (+0.58%)
Tom Gayner 248,000 sh (+0.40%)
John Paulson Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Jeremy Grantham 1,140,718 sh (-0.33%)
Mairs and Power 2,879 sh (-2.37%)
PRIMECAP Management 3,409,100 sh (-2.39%)
Ruane Cunniff 13,401 sh (-2.90%)
David Dreman 8,061 sh (-12.24%)
Murray Stahl 2,767 sh (-13.45%)
Jim Simons 724,505 sh (-22.93%)
Jerome Dodson 186,000 sh (-27.34%)
» More
Q1 2017

CVS Guru Trades in Q1 2017

Charles Brandes 94,271 sh (New)
Richard Snow 288,876 sh (+7130.94%)
John Rogers 115,681 sh (+245.33%)
Paul Tudor Jones 59,741 sh (+106.39%)
Jim Simons 1,414,005 sh (+95.17%)
Ken Fisher 263,189 sh (+95.07%)
Steven Cohen 210,612 sh (+86.55%)
David Dreman 13,849 sh (+71.80%)
Ray Dalio 161,883 sh (+48.50%)
Jeff Auxier 67,049 sh (+8.06%)
Tom Gayner 264,000 sh (+6.45%)
Mairs and Power 3,034 sh (+5.38%)
Pioneer Investments 8,033,087 sh (+4.60%)
John Buckingham 46,844 sh (+3.50%)
Joel Greenblatt 1,082,388 sh (+2.51%)
Mario Gabelli 1,092,787 sh (+1.98%)
First Pacific Advisors 163,580 sh (+1.10%)
Scott Black 24,455 sh (+0.88%)
Wallace Weitz 122,123 sh (+0.79%)
Richard Pzena 534,035 sh (+0.05%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 2,767 sh (unchged)
Steven Cohen 1,154,300 sh (unchged)
Charles de Vaulx 1,384,235 sh (unchged)
PRIMECAP Management 3,391,470 sh (-0.52%)
Arnold Van Den Berg 68,655 sh (-1.56%)
Jeremy Grantham 1,103,290 sh (-3.28%)
Barrow, Hanley, Mewhinney & Strauss 17,400,999 sh (-4.81%)
Ruane Cunniff 12,701 sh (-5.22%)
Robert Olstein 121,925 sh (-12.91%)
NWQ Managers 1,014,208 sh (-25.02%)
Manning & Napier Advisors, Inc 141,680 sh (-25.47%)
Signature Select Canadian Fund 43,603 sh (-25.97%)
Jerome Dodson 106,000 sh (-43.01%)
» More
Q2 2017

CVS Guru Trades in Q2 2017

First Pacific Advisors 433,092 sh (+164.76%)
Manning & Napier Advisors, Inc 296,527 sh (+109.29%)
David Dreman 26,788 sh (+93.43%)
Arnold Van Den Berg 105,540 sh (+53.73%)
Richard Pzena 700,074 sh (+31.09%)
Mairs and Power 3,254 sh (+7.25%)
Murray Stahl 2,917 sh (+5.42%)
John Buckingham 48,797 sh (+4.17%)
Jeremy Grantham 1,132,600 sh (+2.66%)
Robert Olstein 124,925 sh (+2.46%)
Tom Gayner 267,000 sh (+1.14%)
Jeff Auxier 67,449 sh (+0.60%)
Charles Brandes 94,408 sh (+0.15%)
Jerome Dodson 106,000 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Charles de Vaulx 1,384,235 sh (unchged)
Ray Dalio Sold Out
Richard Snow Sold Out
Jim Simons Sold Out
Ruane Cunniff Sold Out
Paul Tudor Jones Sold Out
John Rogers 115,661 sh (-0.02%)
PRIMECAP Management 3,366,250 sh (-0.74%)
Mario Gabelli 1,080,522 sh (-1.12%)
Ken Fisher 259,678 sh (-1.33%)
Barrow, Hanley, Mewhinney & Strauss 17,044,120 sh (-2.05%)
Scott Black 23,735 sh (-2.94%)
Wallace Weitz 113,291 sh (-7.23%)
Steven Cohen 192,200 sh (-8.74%)
Pioneer Investments 6,329,573 sh (-21.21%)
NWQ Managers 730,987 sh (-27.93%)
Joel Greenblatt 761,094 sh (-29.68%)
» More
Q3 2017

CVS Guru Trades in Q3 2017

Larry Robbins 1,369,003 sh (New)
Caxton Associates 3,800 sh (New)
Jeff Auxier 69,599 sh (+3.19%)
Murray Stahl 2,967 sh (+1.71%)
John Buckingham 49,528 sh (+1.50%)
Ken Fisher 261,022 sh (+0.52%)
John Rogers 115,894 sh (+0.20%)
PRIMECAP Management 3,369,520 sh (+0.10%)
Jerome Dodson 106,000 sh (unchged)
Tom Gayner 267,000 sh (unchged)
Wallace Weitz 113,291 sh (unchged)
Scott Black Sold Out
Richard Pzena 699,872 sh (-0.03%)
First Pacific Advisors 424,652 sh (-1.95%)
Arnold Van Den Berg 102,535 sh (-2.85%)
Mario Gabelli 1,049,236 sh (-2.90%)
Joel Greenblatt 727,254 sh (-4.45%)
Robert Olstein 119,000 sh (-4.74%)
Barrow, Hanley, Mewhinney & Strauss 16,207,787 sh (-4.91%)
David Dreman 25,417 sh (-5.12%)
Jeremy Grantham 1,065,011 sh (-5.97%)
Pioneer Investments 5,780,484 sh (-8.67%)
Mairs and Power 2,743 sh (-15.70%)
NWQ Managers 610,109 sh (-16.54%)
Charles Brandes 59,942 sh (-36.51%)
Manning & Napier Advisors, Inc 156,712 sh (-47.15%)
Steven Cohen 35,000 sh (-81.79%)
» More
» Details

Insider Trades

Latest Guru Trades with CVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -4.91%0.1%$75.35 - $83.31 $ 70.55-11%16,207,787
Mario Gabelli 2017-09-30 Reduce -2.90%0.02%$75.35 - $83.31 $ 70.55-11%1,049,236
Joel Greenblatt 2017-09-30 Reduce -4.45%0.04%$75.35 - $83.31 $ 70.55-11%727,254
Richard Pzena 2017-09-30 Reduce -0.03%$75.35 - $83.31 $ 70.55-11%699,872
NWQ Managers 2017-09-30 Reduce -16.54%0.13%$75.35 - $83.31 $ 70.55-11%610,109
Ken Fisher 2017-09-30 Add 0.52%$75.35 - $83.31 $ 70.55-11%261,022
Robert Olstein 2017-09-30 Reduce -4.74%0.06%$75.35 - $83.31 $ 70.55-11%119,000
John Rogers 2017-09-30 Add 0.20%$75.35 - $83.31 $ 70.55-11%115,894
Arnold Van Den Berg 2017-09-30 Reduce -2.85%0.04%$75.35 - $83.31 $ 70.55-11%102,535
Charles Brandes 2017-09-30 Reduce -36.51%0.04%$75.35 - $83.31 $ 70.55-11%59,942
David Dreman 2017-09-30 Reduce -5.12%0.06%$75.35 - $83.31 $ 70.55-11%25,417
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -2.05%0.04%$75.95 - $82.79 $ 70.55-11%17,044,120
Mario Gabelli 2017-06-30 Reduce -1.12%0.01%$75.95 - $82.79 $ 70.55-11%1,080,522
Joel Greenblatt 2017-06-30 Reduce -29.68%0.32%$75.95 - $82.79 $ 70.55-11%761,094
NWQ Managers 2017-06-30 Reduce -27.93%0.3%$75.95 - $82.79 $ 70.55-11%730,987
Richard Pzena 2017-06-30 Add 31.09%0.07%$75.95 - $82.79 $ 70.55-11%700,074
Tom Gayner 2017-06-30 Add 1.14%0.01%$75.95 - $82.79 $ 70.55-11%267,000
Ken Fisher 2017-06-30 Reduce -1.33%$75.95 - $82.79 $ 70.55-11%259,678
Robert Olstein 2017-06-30 Add 2.46%0.03%$75.95 - $82.79 $ 70.55-11%124,925
John Rogers 2017-06-30 Reduce -0.02%$75.95 - $82.79 $ 70.55-11%115,661
Wallace Weitz 2017-06-30 Reduce -7.23%0.03%$75.95 - $82.79 $ 70.55-11%113,291
Arnold Van Den Berg 2017-06-30 Add 53.73%0.46%$75.95 - $82.79 $ 70.55-11%105,540
Charles Brandes 2017-06-30 Add 0.15%$75.95 - $82.79 $ 70.55-11%94,408
David Dreman 2017-06-30 Add 93.43%0.57%$75.95 - $82.79 $ 70.55-11%26,788
Ruane Cunniff 2017-06-30 Sold Out 0.01%$75.95 - $82.79 $ 70.55-11%0
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -4.81%0.1%$74.8 - $83.92 $ 70.55-12%17,400,999
Mario Gabelli 2017-03-31 Add 1.98%0.01%$74.8 - $83.92 $ 70.55-12%1,092,787
Joel Greenblatt 2017-03-31 Add 2.51%0.03%$74.8 - $83.92 $ 70.55-12%1,082,388
NWQ Managers 2017-03-31 Reduce -25.02%0.36%$74.8 - $83.92 $ 70.55-12%1,014,208
Richard Pzena 2017-03-31 Add 0.05%$74.8 - $83.92 $ 70.55-12%534,035
Tom Gayner 2017-03-31 Add 6.45%0.03%$74.8 - $83.92 $ 70.55-12%264,000
Ken Fisher 2017-03-31 Add 95.07%0.01%$74.8 - $83.92 $ 70.55-12%263,189
Wallace Weitz 2017-03-31 Add 0.79%$74.8 - $83.92 $ 70.55-12%122,123
Robert Olstein 2017-03-31 Reduce -12.91%0.18%$74.8 - $83.92 $ 70.55-12%121,925
John Rogers 2017-03-31 Add 245.33%0.08%$74.8 - $83.92 $ 70.55-12%115,681
Charles Brandes 2017-03-31 New Buy0.11%$74.8 - $83.92 $ 70.55-12%94,271
Arnold Van Den Berg 2017-03-31 Reduce -1.56%0.01%$74.8 - $83.92 $ 70.55-12%68,655
David Dreman 2017-03-31 Add 71.80%0.26%$74.8 - $83.92 $ 70.55-12%13,849
Ruane Cunniff 2017-03-31 Reduce -5.22%$74.8 - $83.92 $ 70.55-12%12,701
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Add 100.88%1.08%$73.53 - $88.8 $ 70.55-13%18,280,528
NWQ Managers 2016-12-31 Add 44.82%0.45%$73.53 - $88.8 $ 70.55-13%1,352,559
Mario Gabelli 2016-12-31 Add 0.58%$73.53 - $88.8 $ 70.55-13%1,071,617
Joel Greenblatt 2016-12-31 Add 139.61%0.62%$73.53 - $88.8 $ 70.55-13%1,055,841
Richard Pzena 2016-12-31 Add 0.73%$73.53 - $88.8 $ 70.55-13%533,748
Tom Gayner 2016-12-31 Add 0.40%$73.53 - $88.8 $ 70.55-13%248,000
Robert Olstein 2016-12-31 Add 29.63%0.32%$73.53 - $88.8 $ 70.55-13%140,000
Ken Fisher 2016-12-31 Add 1.64%$73.53 - $88.8 $ 70.55-13%134,917
Wallace Weitz 2016-12-31 New Buy0.39%$73.53 - $88.8 $ 70.55-13%121,162
Arnold Van Den Berg 2016-12-31 New Buy0.87%$73.53 - $88.8 $ 70.55-13%69,740
John Rogers 2016-12-31 New Buy0.03%$73.53 - $88.8 $ 70.55-13%33,499
Ruane Cunniff 2016-12-31 Reduce -2.90%$73.53 - $88.8 $ 70.55-13%13,401
David Dreman 2016-12-31 Reduce -12.24%0.06%$73.53 - $88.8 $ 70.55-13%8,061
John Paulson 2016-12-31 Sold Out 0.12%$73.53 - $88.8 $ 70.55-13%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 621399    SIC: 8099
Compare:NYSE:AET, NYSE:ANTM, NYSE:CI, NYSE:HUM, NAS:ESRX, NYSE:CNC, NYSE:WCG, NYSE:MOH, BSP:QUAL3, BSP:ODPV3, NAS:MGLN, XPAR:GDS, OSTO:MCOV B, NAS:HIIQ, ATH:IATR, ASX:ONT, MIL:HI, OTCPK:HFRN, OSTO:FEEL, OTCPK:OPRX » details
Traded in other countries:CVSH34.Brazil, CVS.Chile, CVS.Germany, CVS.Mexico,
Headquarter Location:USA
CVS Health Corp operates in the healthcare sector. Its primary business is that of operating retail pharmacies.

CVS Health has vertically integrated one of the largest retail pharmacy chains in the United States with one of the largest pharmacy benefit managers. This combination makes it one of the premier healthcare firms in the U.S. The company processes approximately 1.3 billion prescriptions per year and operates more than 10,000 retail pharmacies across the U.S.

Guru Investment Theses on CVS Health Corp

Weitz Funds Comments on CVS Health - Jan 26, 2017

CVS Health (NYSE:CVS) operates a nationwide network of nearly 10,000 retail pharmacies, the nation’s second largest pharmacy benefits manager (PBM) in Caremark, and sizeable specialty and long-term care pharmacy platforms. This is the fund’s second go around with CVS, having last owned it back in 2013. CVS’ stock has been under pressure for most of the last 18 months after peaking during the summer of 2015. After nearly five years of consistent market share gains, the Caremark PBM suffered several client losses over the course of 2016. In addition, CVS also announced that its retail pharmacies would no longer be part of several important networks in 2017. These lost volumes will likely result in no earnings per share growth this year. These near-term negatives drove the stock down to a price that we found attractive. While management will need to navigate several risks over the course of the next couple of years, we believe CVS’ stock price provides an attractive valuation in the mid-$70s.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Mario Gabelli Comments on CVS Health Corp - Nov 02, 2016

CVS Health Corp. (NYSE:CVS) (2.3%) (CVS – $88.99 – NYSE) is the leading pharmacy and pharmacy benefits manager in the country, with over $150 billion in annual revenue. The stock declined in the quarter due to the significant political scrutiny around drug pricing. Efforts to regulate and control drug pricing could have an indirect impact on CVS’s revenues and earnings. However, we believe the company is a low cost provider who already works aggressively to improve health through the dispensing of low cost generic drugs, coordination of care, and efforts to improve adherence by patients.



From Mario Gabelli (Trades, Portfolio)'s Equity Income Fund 3rd quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Mario Gabelli Comments on CVS Health Corp - Feb 05, 2016

CVS Health Corp. (2.4%) (CVS – $97.77 – NYSE)(NYSE:CVS) is the leading pharmacy and pharmacy benefits manager in the country, with over $150 billion in annual revenue. The company’s recent acquisitions of institutional pharmacy Omnicare and the pharmacies inside Target stores should add $0.15 to earnings in 2016 and further CVS’s dominance across the pharmacy channel. Same store sales should improve in 2016 now that the company has annualized its decision to stop selling tobacco, and that decision has helped them win over $11 billion in net new business for its pharmacy benefits management (PBM) division.

From Mario Gabelli (Trades, Portfolio)'s GAMCO Equity Income Fund fourth quarter 2015 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about CVS Health Corp

CVS Pharmacy's Exclusive Black Friday and Cyber Monday promotions help customers save time and money, and find joy in the little things that matter most
CVS Health Commits to Hiring 5,000 New Apprentices by 2022, Expands States Participating in the Program
CVS Health Earns Perfect Score in 2018 Corporate Equality Index
52-Week Company Lows Prices for AT&T, GE, Merck, CVS Health, Time Warner and TJX Companies fall
According to GuruFocus’ list, these stocks have reached their 52-week lows. Read more...
CVS Health Makes Overdose-Reversal Drug Available Without Individual Prescription at CVS Pharmacy Locations in Oklahoma
CVS Health Makes Overdose-Reversal Drug Available Without Individual Prescription at CVS Pharmacy Locations in Delaware
CVS Health Makes Overdose-Reversal Drug Available Without Individual Prescription at CVS Pharmacy Locations in Michigan
CVS Health Joins with the National Consortium of State-Operated Comprehensive Rehabilitation Centers to Help More Americans with Disabilities Find Meaningful Employment
CVS Pharmacy to Bring Prescriptions Right to Customers' Doors with Nationwide Next-Day Delivery and Same-Day Delivery in Select Markets
Thinking about investing in CVS Health Corp, Intel, Metlife Incorporated, Qualcomm or Sprint Corp?

Ratios

vs
industry
vs
history
PE Ratio 14.61
CVS's PE Ratio is ranked higher than
67% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.90 vs. CVS: 14.61 )
Ranked among companies with meaningful PE Ratio only.
CVS' s PE Ratio Range Over the Past 10 Years
Min: 10.58  Med: 17.12 Max: 27.17
Current: 14.61
10.58
27.17
Forward PE Ratio 11.26
CVS's Forward PE Ratio is ranked higher than
73% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.85 vs. CVS: 11.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 14.58
CVS's PE Ratio without NRI is ranked higher than
71% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 20.71 vs. CVS: 14.58 )
Ranked among companies with meaningful PE Ratio without NRI only.
CVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.62  Med: 17.04 Max: 27.17
Current: 14.58
10.62
27.17
Price-to-Owner-Earnings 9.33
CVS's Price-to-Owner-Earnings is ranked higher than
56% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.97 vs. CVS: 9.33 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.46  Med: 19.3 Max: 60.62
Current: 9.33
8.46
60.62
PB Ratio 2.05
CVS's PB Ratio is ranked higher than
68% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.89 vs. CVS: 2.05 )
Ranked among companies with meaningful PB Ratio only.
CVS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.79 Max: 3.37
Current: 2.05
1.01
3.37
PS Ratio 0.40
CVS's PS Ratio is ranked higher than
76% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.58 vs. CVS: 0.40 )
Ranked among companies with meaningful PS Ratio only.
CVS' s PS Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.56 Max: 0.88
Current: 0.4
0.39
0.88
Price-to-Free-Cash-Flow 8.95
CVS's Price-to-Free-Cash-Flow is ranked higher than
61% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.51 vs. CVS: 8.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.34  Med: 19.96 Max: 79.81
Current: 8.95
8.34
79.81
Price-to-Operating-Cash-Flow 7.17
CVS's Price-to-Operating-Cash-Flow is ranked higher than
60% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.80 vs. CVS: 7.17 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.72  Med: 12.13 Max: 19.92
Current: 7.17
6.72
19.92
EV-to-EBIT 10.27
CVS's EV-to-EBIT is ranked higher than
71% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.46 vs. CVS: 10.27 )
Ranked among companies with meaningful EV-to-EBIT only.
CVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.6  Med: 11.1 Max: 20.4
Current: 10.27
7.6
20.4
EV-to-EBITDA 8.09
CVS's EV-to-EBITDA is ranked higher than
61% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.98 vs. CVS: 8.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
CVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 8.9 Max: 16
Current: 8.09
6.2
16
EV-to-Revenue 0.52
CVS's EV-to-Revenue is ranked higher than
62% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.83 vs. CVS: 0.52 )
Ranked among companies with meaningful EV-to-Revenue only.
CVS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 0.6 Max: 1.2
Current: 0.52
0.5
1.2
PEG Ratio 1.04
CVS's PEG Ratio is ranked higher than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.73 vs. CVS: 1.04 )
Ranked among companies with meaningful PEG Ratio only.
CVS' s PEG Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.32 Max: 2.34
Current: 1.04
0.57
2.34
Shiller PE Ratio 19.42
CVS's Shiller PE Ratio is ranked higher than
69% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 25.17 vs. CVS: 19.42 )
Ranked among companies with meaningful Shiller PE Ratio only.
CVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.19  Med: 24.69 Max: 39.08
Current: 19.42
17.19
39.08
Current Ratio 1.05
CVS's Current Ratio is ranked lower than
52% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.16 vs. CVS: 1.05 )
Ranked among companies with meaningful Current Ratio only.
CVS' s Current Ratio Range Over the Past 10 Years
Min: 1.05  Med: 1.53 Max: 2.64
Current: 1.05
1.05
2.64
Quick Ratio 0.55
CVS's Quick Ratio is ranked lower than
83% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.16 vs. CVS: 0.55 )
Ranked among companies with meaningful Quick Ratio only.
CVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.51 Max: 0.93
Current: 0.55
0.2
0.93
Days Inventory 34.03
CVS's Days Inventory is ranked lower than
78% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.19 vs. CVS: 34.03 )
Ranked among companies with meaningful Days Inventory only.
CVS' s Days Inventory Range Over the Past 10 Years
Min: 34.03  Med: 41.44 Max: 50.81
Current: 34.03
34.03
50.81
Days Sales Outstanding 24.90
CVS's Days Sales Outstanding is ranked higher than
72% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 32.83 vs. CVS: 24.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.77  Med: 22.19 Max: 28.31
Current: 24.9
18.77
28.31
Days Payable 18.71
CVS's Days Payable is ranked lower than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 49.78 vs. CVS: 18.71 )
Ranked among companies with meaningful Days Payable only.
CVS' s Days Payable Range Over the Past 10 Years
Min: 16.69  Med: 19.59 Max: 21.78
Current: 18.71
16.69
21.78

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.84
CVS's Dividend Yield % is ranked higher than
83% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.41 vs. CVS: 2.84 )
Ranked among companies with meaningful Dividend Yield % only.
CVS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.42  Med: 1.19 Max: 2.84
Current: 2.84
0.42
2.84
Dividend Payout Ratio 0.40
CVS's Dividend Payout Ratio is ranked lower than
73% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 9999.00 vs. CVS: 0.40 )
Ranked among companies with meaningful Dividend Payout Ratio only.
CVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.2 Max: 0.4
Current: 0.4
0.11
0.4
3-Year Dividend Growth Rate 23.60
CVS's 3-Year Dividend Growth Rate is ranked higher than
75% of the 8 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.90 vs. CVS: 23.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -33.8  Med: 8 Max: 37
Current: 23.6
-33.8
37
Forward Dividend Yield % 2.80
CVS's Forward Dividend Yield % is ranked higher than
93% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.53 vs. CVS: 2.80 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 9.72
CVS's 5-Year Yield-on-Cost % is ranked higher than
85% of the 40 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.99 vs. CVS: 9.72 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.44  Med: 4.07 Max: 9.72
Current: 9.72
1.44
9.72
3-Year Average Share Buyback Ratio 3.50
CVS's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.30 vs. CVS: 3.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.9  Med: -0.4 Max: 4.7
Current: 3.5
-22.9
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.62
CVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.19 vs. CVS: 0.62 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.36 Max: 26.44
Current: 0.62
0.62
26.44
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.91
CVS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
78% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.51 vs. CVS: 0.91 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
CVS' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.54  Med: 0.74 Max: 1.48
Current: 0.91
0.54
1.48
Price-to-Median-PS-Value 0.72
CVS's Price-to-Median-PS-Value is ranked higher than
75% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.10 vs. CVS: 0.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45  Med: 0.95 Max: 2.65
Current: 0.72
0.45
2.65
Price-to-Peter-Lynch-Fair-Value 1.23
CVS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
73% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.62 vs. CVS: 1.23 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CVS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.44 Max: 6.55
Current: 1.23
0.64
6.55
Earnings Yield (Greenblatt) % 9.74
CVS's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.07 vs. CVS: 9.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.9  Med: 9 Max: 13.2
Current: 9.74
4.9
13.2
Forward Rate of Return (Yacktman) % 19.56
CVS's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.68 vs. CVS: 19.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.8  Med: 18.1 Max: 24.2
Current: 19.56
11.8
24.2

More Statistics

Revenue (TTM) (Mil) $182,351.00
EPS (TTM) $ 4.83
Beta0.50
Short Percentage of Float2.40%
52-Week Range $66.45 - 84.72
Shares Outstanding (Mil)1,012.99

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 184,228 193,562 205,636
EPS ($) 5.70 6.25 6.95
EPS without NRI ($) 5.70 6.25 6.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)
16.25%
Dividends per Share ($) 1.92 2.12 3.08

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}